Insider Trading Alert - VRTX, NATI, CLX, SN And IBKR Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Jan. 8, 2014, 79 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1,000.20 to $12,860,510.00.

Highlighted Stocks Traded by Insiders:

Vertex Pharmaceuticals (VRTX) - FREE Research Report

Pace Megan E who is SVP, Corp. Communications at Vertex Pharmaceuticals sold 838 shares at $75.00 on Jan. 8, 2014. Following this transaction, the SVP, Corp. Communications owned 11,350 shares meaning that the stake was reduced by 6.88% with the 838-share transaction.

The shares most recently traded at $75.68, up $0.68, or 0.9% since the insider transaction. Historical insider transactions for Vertex Pharmaceuticals go as follows:

  • 4-Week # shares sold: 36,692
  • 12-Week # shares sold: 54,285
  • 24-Week # shares sold: 83,649

The average volume for Vertex Pharmaceuticals has been 1.9 million shares per day over the past 30 days. Vertex Pharmaceuticals has a market cap of $17.4 billion and is part of the health care sector and drugs industry. Shares are up 1.25% year-to-date as of the close of trading on Wednesday.

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Currently there are 13 analysts that rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VRTX - FREE

TheStreet Quant Ratings rates Vertex Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full Vertex Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

National Instruments Corporation (NATI) - FREE Research Report

Kodosky Jeffrey L who is Director at National Instruments Corporation sold 4,000 shares at $30.69 on Jan. 8, 2014. Following this transaction, the Director owned 973,180 shares meaning that the stake was reduced by 0.41% with the 4,000-share transaction.

The shares most recently traded at $31.59, up $0.90, or 2.86% since the insider transaction. Historical insider transactions for National Instruments Corporation go as follows:

  • 4-Week # shares sold: 3,000
  • 12-Week # shares sold: 37,271
  • 24-Week # shares sold: 85,271

The average volume for National Instruments Corporation has been 356,200 shares per day over the past 30 days. National Instruments Corporation has a market cap of $3.9 billion and is part of the technology sector and computer software & services industry. Shares are down 2.22% year-to-date as of the close of trading on Wednesday.

National Instruments Corporation designs, manufactures, and sells tools to engineers and scientists worldwide. It offers LabVIEW, a system design software product for measurement and control; and LabVIEW Real-Time and LabVIEW FPGA that are strategic modular software add-ons. The stock currently has a dividend yield of 1.79%. The company has a P/E ratio of 56.9. Currently there is 1 analyst that rates National Instruments Corporation a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NATI - FREE

TheStreet Quant Ratings rates National Instruments Corporation as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had somewhat weak growth in earnings per share. Get the full National Instruments Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Clorox Company (CLX) - FREE Research Report

Tataseo Frank A who is EVP - Prof. Products Div. at Clorox Company sold 657 shares at $91.22 on Jan. 8, 2014. Following this transaction, the EVP - Prof. Products Div. owned 4,724 shares meaning that the stake was reduced by 12.21% with the 657-share transaction.

The shares most recently traded at $89.48, down $1.74, or 1.95% since the insider transaction. Historical insider transactions for Clorox Company go as follows:

  • 4-Week # shares sold: 1,625
  • 12-Week # shares sold: 8,030
  • 24-Week # shares sold: 8,030

The average volume for Clorox Company has been 1.2 million shares per day over the past 30 days. Clorox Company has a market cap of $11.7 billion and is part of the consumer goods sector and consumer durables industry. Shares are down 4.06% year-to-date as of the close of trading on Wednesday.

The Clorox Company manufactures and markets consumer and professional products worldwide. The stock currently has a dividend yield of 3.14%. The company has a P/E ratio of 20.9. Currently there is 1 analyst that rates Clorox Company a buy, 3 analysts rate it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CLX - FREE

TheStreet Quant Ratings rates Clorox Company as a buy. The company's strengths can be seen in multiple areas, such as its notable return on equity, revenue growth, increase in stock price during the past year, growth in earnings per share and expanding profit margins. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Clorox Company Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Sanchez Energy (SN) - FREE Research Report

Garcia Gilbert A who is Director at Sanchez Energy bought 1,000 shares at $24.44 on Jan. 8, 2014. Following this transaction, the Director owned 30,200 shares meaning that the stake was reduced by 3.42% with the 1,000-share transaction.

The shares most recently traded at $24.33, down $0.11, or 0.45% since the insider transaction. Historical insider transactions for Sanchez Energy go as follows:

  • 4-Week # shares bought: 800
  • 4-Week # shares sold: 1,273
  • 12-Week # shares bought: 800
  • 12-Week # shares sold: 1,273
  • 24-Week # shares bought: 3,800
  • 24-Week # shares sold: 1,273

The average volume for Sanchez Energy has been 741,600 shares per day over the past 30 days. Sanchez Energy has a market cap of $1.1 billion and is part of the basic materials sector and energy industry. Shares are down 2.28% year-to-date as of the close of trading on Wednesday.

Sanchez Energy Corporation, an independent exploration and production company, focuses on the acquisition, exploration, and development of unconventional oil and natural gas resources. Currently there are 9 analysts that rate Sanchez Energy a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on SN - FREE

TheStreet Quant Ratings rates Sanchez Energy as a sell. Among the areas we feel are negative, one of the most important has been the company's poor growth in earnings per share. Get the full Sanchez Energy Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Interactive Brokers Group (IBKR) - FREE Research Report

Galik Milan who is SVP Software Development at Interactive Brokers Group sold 2,000 shares at $24.44 on Jan. 8, 2014. Following this transaction, the SVP Software Development owned 841,517 shares meaning that the stake was reduced by 0.24% with the 2,000-share transaction.

The shares most recently traded at $23.38, down $1.06, or 4.53% since the insider transaction. Historical insider transactions for Interactive Brokers Group go as follows:

  • 4-Week # shares sold: 15,000
  • 12-Week # shares sold: 51,000
  • 24-Week # shares sold: 110,000

The average volume for Interactive Brokers Group has been 540,800 shares per day over the past 30 days. Interactive Brokers Group has a market cap of $1.2 billion and is part of the financial sector and financial services industry. Shares are down 4.48% year-to-date as of the close of trading on Wednesday.

Interactive Brokers Group, Inc. operates as an automated electronic broker and market maker. The stock currently has a dividend yield of 1.65%. The company has a P/E ratio of 28.1. Currently there are 2 analysts that rate Interactive Brokers Group a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on IBKR - FREE

TheStreet Quant Ratings rates Interactive Brokers Group as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, increase in net income, revenue growth, reasonable valuation levels and good cash flow from operations. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Interactive Brokers Group Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research
null

If you liked this article you might like

Biotech, Pharma Stocks Tumble Amid Big Market Sell-Off

Biotech, Pharma Stocks Tumble Amid Big Market Sell-Off

Feed the Beast: Cramer's 'Mad Money' Recap (Thursday 1/4/18)

Feed the Beast: Cramer's 'Mad Money' Recap (Thursday 1/4/18)

Cramer: 2017 Was a Year of Resurrection and Revival

Cramer: 2017 Was a Year of Resurrection and Revival

Dow Jumps After Fed Rate Hike, Posts New Record for Fourth Straight Day

Dow Jumps After Fed Rate Hike, Posts New Record for Fourth Straight Day

Dow, S&P 500 on Track to Extend Winning Streaks to 5 Days Before Fed Meeting

Dow, S&P 500 on Track to Extend Winning Streaks to 5 Days Before Fed Meeting